NPF Expands Seal of Recognition to FDA-approved Treatments; First Seal Goes to Roflumilast 0.3% (Zoryve, Arcutis)
The National Psoriasis Foundation has expanded its Seal of Recognition to include U.S Food and Drug Administration (FDA)-approved prescription drugs to better represent the full toolbox of options available for people with psoriatic disease. The first such Seal of Recognition goes to roflumilast cream 0.3% and roflumilast topical foam 0.3% (Zoryve, Arcutis), both FDA approved […]